661 related articles for article (PubMed ID: 27298192)
1. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
2. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
3. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Jung E; Kim J; Kim SH; Kim S; Cho MH
Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Choi SH; Park S; Oh CJ; Leem J; Park KG; Lee IK
Vascul Pharmacol; 2015 Oct; 73():11-9. PubMed ID: 26187356
[TBL] [Abstract][Full Text] [Related]
5. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
Jain MR; Joharapurkar AA; Bahekar RH; Patel H; Jadav P; Kshirsagar SG; Patel VJ; Patel KN; Ramanathan VK; Patel PR; Desai RC
J Diabetes; 2015 Sep; 7(5):708-17. PubMed ID: 25327540
[TBL] [Abstract][Full Text] [Related]
7. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
[TBL] [Abstract][Full Text] [Related]
8. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Choi SH; Leem J; Lee IK
Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
[TBL] [Abstract][Full Text] [Related]
9. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
11. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
13. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
[TBL] [Abstract][Full Text] [Related]
14. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim SH; Lee SH; Yim HJ
Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
Davis JA; Kumar PS; Singh S; Surender A; Roy S; Khanna V; Sethi S; Pal C; Sharma L; Benjamin B; Mittra S; Sattigeri J; Bansal VS
Indian J Pharmacol; 2012; 44(6):759-64. PubMed ID: 23248408
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
18. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
[TBL] [Abstract][Full Text] [Related]
19. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
[TBL] [Abstract][Full Text] [Related]
20. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Jain MR; Joharapurkar AA; Kshirsagar SG; Patel VJ; Bahekar RH; Patel HV; Jadav PA; Patel PR; Desai RC
Br J Pharmacol; 2017 Jul; 174(14):2346-2357. PubMed ID: 28452143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
